摘要
Although chimeric antigen receptor T-cell(CAR-T-cell)therapy has shown excellent efficacy against refractory/relapsed B-cell lymphoma,B-cell acute lymphoblastic leukemia and multiple myeloma,1,2 the complete response rate of patients with refractory/relapsed B-cell lymphoma receiving conventional CAR-T-cell therapy is approximately 40%to 50%.3–5 There are 3 drawbacks to viral CAR-T-cell therapy.First,random integration of the CAR cassette and lentivirus replication are potential risks for viral CAR-T-cell therapy(Fig.1A).
